O nly 20-40% of adults who have acute myeloid leukaemia (AML) survive in the long term 1 . Several large-scale genome-sequencing efforts have attempted to define mutations associated with AML, with a view to identifying new therapeutic strategies 2 . These analyses have uncovered many recurrent mutations in epigenetic regulator proteins, which modulate gene expression by altering the 3D structure of chromosomes. Epigenetic regulators include enzymes that attach and remove molecular modifications on DNA. Writing in Cancer Discovery, Yen et al. 3 and Shih et al. 4 present evidence that mutations in two enzymes, IDH2 and TET2, that lead to altered epigenetic regulation, can be targeted therapeutically in AML cells, providing a compelling rationale for further development of epigenetically targeted anticancer treatments.
The enzyme TET2 is a dioxygenase that depends on the molecule a-ketoglutarate (a-KG) for its activity (Fig. 1) . It catalyses the addition of a hydroxyl group to 5-methylcytosine (5mC) -a form of the DNA base cytosine that has been modified by the attachment of a methyl moiety -to produce 5-hydroxymethylcytosine (5hmC) 5 . The formation of 5hmC is an important step in converting 5mC into unmethylated cytosine. Inactivating mutations in the TET2 gene decrease 5hmC levels and lead to the accumulation of 5mC. This DNA hyper methylation leads to changes in gene expression that promote the proliferation of long-lived TET2-mutant haematopoietic stem cells, and disrupt their differentiation into various types of blood cell, thereby promoting AML.
Most other AML-associated mutations in genes that encode epigenetic regulators cause protein inactivation, but mutations in IDH genes are an exception. Both IDH1 and IDH2 are metabolic enzymes that normally catalyse the interconversion of a-KG and another molecule, isocitrate. But cancerassociated mutations alter their activity 6 such that they instead convert a-KG to (R)-2-hydroxy glutarate (2HG), which is structurally similar to a-KG and can competitively inhibit several a-KG-dependent enzymes 7 , including TET2 (Fig. 1) .
A previous study 8 showed that the leukaemic effects of mutant IDH enzymes require the sustained production of 2HG. Furthermore, drugs that inhibit the activity of mutant IDHs lower intracellular levels of 2HG and promote the differentiation of immature, IDH-mutant AML cells into mature white blood cells, both in vitro and in mice 9 . Mature white blood cells have a limited capacity to proliferate and are short-lived, so the inhibition of mutant IDH reduces the leukaemia-cell pool. However, these experiments were performed using 'tool' compounds, which, although highly potent, have not been pharmacologically optimized for use in humans.
In one of the two current studies, Yen et al. 
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Modification of methyl groups attached to DNA alters gene expression, and mutations that deregulate this methylation are common in some leukaemias. Drugs that target aberrant methylation are emerging as promising therapeutics.
chains and the impacts of imported goods. Such global assessments are a first step towards improving the sustainability of worldwide food production, because they provide fresh data and perspectives on the big picture and on the drivers of water use and abuse. A consideration of trade-related environmental concerns might also suggest new global watergovernance solutions, which could be applied by introducing measures to ensure that existing food-trade frameworks of the European Single The enzyme TET2, with the co-factor molecule a-ketoglutarate (a-KG), converts 5mC to 5-hydroxymethylcytosine (5hmC), which can be demethylated to form cytosine again. Mutations that cause the loss of TET2 function lead to accumulation of 5mc (not shown), which promotes acute myeloid leukaemia (AML). Mutant forms of IDH enzymes also promote AML. The enzymes convert a-KG to the structurally similar (R)-2-hydroxyglutarate (2HG), which competes with a-KG and so inhibits the activity of TET2. Yen et al. 3 developed a drug called AG-221 that inhibits mutant IDH2. The drug reduces 2HG levels and restores TET2 activity, thereby reversing 5mC accumulation in mouse models of IDH-mutant AML. Shih et al. 4 showed that a drug called 5-Aza has a similar effect in Tet2-mutant AML in mice. 5-Aza inhibits the conversion of cytosine to 5mC, thereby preventing 5mC from accumulating. differentiate into mature white blood cells. Furthermore, treatment with AG-221 prolonged the survival of mice transplanted with the AML cells.
It remains to be seen whether these effects will be recapitulated in humans. However, preliminary results 10 from early-phase clinical trials of AG-221 suggest that the drug provides a therapeutic benefit in some people with IDH2-mutant AML. It is less clear whether it will have a similar effect on people who have solid tumours that harbour IDH mutations. In an ongoing phase I clinical trial to test a drug called AG-120 that inhibits mutant IDH1, interim analysis shows that the drug frequently stabilizes the disease in patients with solid tumours, but rarely causes tumour regression (see go.nature.com/2ngnxji).
Mutant IDH proteins are inherently tractable as therapeutic targets because their abnormal function can be inhibited. But restoring the activity of an inactivated enzyme such as TET2 is more difficult. The effect of TET2 loss is to increase DNA methylation, and there is evidence that some TET2-mutant blood cancers are hypersensitive to drugs that inhibit DNA methylation 11 . However, it is not clear whether this reflects a true therapeutic vulnerability of cells that lack TET2, or whether some other feature of these cancers is responsible for this sensitivity.
In the second study, Shih et al. 4 compared the effects of preventing DNA hypermethylation induced by genetic loss of TET2 and restoring TET2 activity by inhibiting mutant IDH2 in AML. The authors generated mice that harboured mutations in either Idh2 or Tet2, in combination with mutations in another gene, Flt3, which encodes a receptor tyrosine kinase protein (an enzyme that activates signalling pathways that promote the proliferation of blood-cell progenitors). Activating mutations in FLT3 are common in AML. In mice, a Flt3 mutation combined with either a Tet2 mutation or an Idh mutation leads to AML.
The authors transplanted the leukaemic cells from their mutant mice into wild-type recipient animals to model conditions in patients, in whom both normal and leukaemic blood cells circulate. They then treated the recipient mice with either AG-221 or a drug called 5-azacytidine (5-Aza), which inhibits DNA methylation. Treatment of mice harbouring Tet2-and Flt3-mutant AML cells with 5-Aza decreased the level of DNA methylation and induced differentiation of the leukaemic cells -as did AG-221 treatment of mice harbouring Idh2-and Flt3-mutant AML cells. However, neither treatment significantly reduced the percentage of circulating blood cells that were derived from the donor mice, suggesting that neither killed a significant portion of the mutant cells.
Shih and colleagues next treated their Tet2-and Flt3-mutant mice with the FLT3 inhibitor AC-220 and 5-Aza, either alone or in combination, and treated their Idh2-and Flt3-mutant mice with AC-220 and AG-221, again either alone or together. Both combination treatments resulted in more-profound responses and increased the reversal of DNA hypermethylation more effectively than the single treatments. Tellingly, the combination therapies dramatically reduced the percentage of circulating cells that were derived from the donor mice, suggesting that two-pronged therapies that target both epigenetic dysregulation and kinase signalling can induce potent antileukaemic responses.
Together, the two current studies provide a valuable proof-of-concept that targeting epigenetic dysregulation could be an effective therapeutic strategy in AML. However, they also suggest that such approaches will not be sufficient to eradicate disease. Instead, Shih and colleagues' data indicate that the key to a cure might lie in dual-pronged therapies. Their work provides a compelling rationale for clinical trials of combined epigenetic-and kinase-targeted therapies.
Finally, it was unexpected that these combination therapies would kill AML cells, and this raises an interesting question: how do epigenetic dysregulation and proliferationpromoting signals interact in AML? Further studies will be required to rule out the possi bility that inhibition of FLT3 signalling simply potentiates the effects of AG-221 and 5-Aza. However, if that is not what happens, then these findings suggest that there is a greater interplay between these (seemingly) functionally distinct pathways than is currently appreciated. A more thorough mechanistic understanding of how these pathways cooperate to promote leukaemia has the potential to uncover exciting new strategies to treat AML. ■ 
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